印度非酒精性脂肪性肝病患者生活习惯改变对肝脏酶和纤维

StephenW

        Effects of lifestyle modification on liver enzyme and Fibroscan in Indian patients with non-alcoholic fatty liver disease
Jayanta Paul
Raj Vigna Venugopal
Lorance Peter
Shihaz Hussain
Kula Naresh Kumar Shetty
Mohit P. Shetti
Gastroenterol Rep (Oxf) gox020.
DOI:
Https://doi.org/10.1093/gastro/gox020
Published:
17 May 2017

Abstract

Background and goal: Non-alcoholic fatty liver disease (NAFLD) is remarkably increasing in developing countries like India, in parallel with the increasing incidence of obesity. Lifestyle modification is a recommended treatment for NAFLD. In most of the previous studies Modified was arrested by liver fibrosis through liver biopsy, but we can not do a serial liver biopsy in every NAFLD patient. Liver fibrosis can also be assessed by fibroscan non-invasively in NAFLD. This study was designed to evaluate the effect of lifestyle modification on liver Enzymes and Fibroscan values in a population with NAFLD.

Methods: Initially, 50 NAFLD patients were included in this prospective follow-up study; however, after 6 months of season modification, only 39 participants were studied. During both the first and second revised, Fibroscan was carried out. All participants underwent a careful Interview, anthropometry measurements and radiological and biochemical tests during every consultation.

Results: After 6 months of lifestyle modification, Fibroscan values improved significantly (8.31 ± 0.11kPa vs 7.87 ± 0.12kPa, p=0.009). Alanine aminotransferase (ALT) values also showed improvement during the second consultation (97.25 ± 2.62 U/L vs 66.69 ± 3.95 U/L, p <0.001).

Conclusion: Measured by Fibroscan and liver enzymes, it has been found that lifestyle modification is an effective therapy to downgrade hepatic injury in NAFLD patients. Serial Fibroscan can be used to assess the treatment response in NAFLD patients due to its non-
Non-alcoholic fatty liver disease, lifestyle modification, alanine aminotransferase, Fibroscan
Topic:

    Obesity consultation liver, injury of hepatic fibrosis alanine transaminase follow-up liver biopsy lifestyle changes non-alcoholic fatty liver disease liver enzyme

Issue Section:
Original Article

StephenW

印度非酒精性脂肪性肝病患者生活习惯改变对肝脏酶和纤维蛋白原的影响
Jayanta保罗
Raj Vigna Venugopal
彼得
Shihaz Hussain
Kula Naresh Kumar Shetty
莫希特·谢蒂
Gastroenterol Rep（Oxf）gox020。
DOI：
Https://doi.org/10.1093/gastro/gox020
发布时间：
2017年5月17日
文章历史

抽象

背景和目标：像印度这样的发展中国家，非酒精性脂肪性肝病（NAFLD）在肥胖发病率上升的同时也显着增加。生活方式修改是NAFLD的推荐治疗方法。在大多数以前的研究中，修饰的肝纤维化通过肝活检被阻止，但是我们不能在每个NAFLD患者中进行连续的肝活检。肝纤维化也可以通过非侵入性的纤维蛋白在NAFLD中进行评估。本研究旨在评估生活方式改变对NAFLD患者肝脏酶和纤维素值的影响。

方法：首先将50例NAFLD患者纳入该前瞻性随访研究;然而，经过6个月的修改，只有39名参与者被研究。在第一次和第二次修订中，进行了Fibroscan。所有参与者在每次咨询期间进行了仔细的面试，人体测量测量和放射和生化测试。

结果：经过6个月的生活习惯改变，Fibroscan值显着改善（8.31±0.11kPa vs 7.87±0.12kPa，p = 0.009）。第二次咨询期间，丙氨酸氨基转移酶（ALT）值也有改善（97.25±2.62 U / L vs 66.69±3.95 U / L，p <0.001）。
结论：通过纤维素和肝酶测定，已经发现生活方式改变是降低NAFLD患者肝损伤的有效方法。连续Fibroscan可用于评估NAFLD患者的治疗反应，
非酒精性脂肪肝疾病，生活方式改变，丙氨酸氨基转移酶，纤维蛋白酶
话题：

肥胖咨询肝脏，肝纤维化损伤丙氨酸转氨酶后续肝活检生活方式改变非酒精性脂肪肝病肝酶

问题部分：
来源文章